Saarland University, Department of Sports Medicine, Saarbrücken, Germany.
Saarland University, Department of Transplant and Infection Immunology, Homburg, Germany.
Exerc Immunol Rev. 2024;30:63-70.
This study analyses the immune response of elite athletes after COVID-19 vaccination with double-dose mRNA and a single-dose vector vaccine.
Immunoglobulin G (IgG) antibody titers, neutralizing activity, CD4 and CD8 T-cells were examined in blood samples from 72 athletes before and after vaccination against COVID-19 (56 mRNA (BNT162b2 / mRNA-1273), 16 vector (Ad26.COV.2) vaccines). Side effects and training time loss was also recorded.
Induction of IgG antibodies (mRNA : 5702 BAU/ml ; 4343 BAU/ml (hereafter: median), vector: 61 BAU/ml ; 52 BAU/ml, p<0.01), their neutralizing activity (99.7% ; 10.6%, p<0.01), and SARS-CoV-2 spike-specific CD4 T-cells (0.13% ; 0.05% ; p<0.01) after mRNA double-dose vaccines was significantly more pronounced than after a single-dose vector vaccine. SARS-CoV-2 spike-specific CD8 T-cell levels after a vector vaccine (0.15%) were significantly higher than after mRNA vaccines (0.02%; p<0.01). When athletes who had initially received the vector vaccine were boostered with an mRNA vaccine, IgG antibodies (to 3456 BAU/ml; p<0.01), neutralizing activity (to 100%; p<0.01), CD4 (to 0.13%; p<0.01) and CD8 T-cells (to 0.43%; p<0.01) significantly increased. When compared with dual-dose mRNA regimen, IgG antibody response was lower (p<0.01), the neutralizing activity (p<0.01) and CD8 T-cell (p<0.01) response higher and no significant difference in CD4 T-cell response (p=0.54) between the two regimens. Cumulative training loss (3 days) did not significantly differ between vaccination regimens (p=0.46).
mRNA and vector vaccines against SARSCoV-2 appear to induce different patterns of immune response in athletes. Lower immune induction after a single-shot vector vaccine was clearly optimized by a heterologous booster. Vaccine reactions were mild and short-lived.
本研究分析了接受两剂 mRNA 和一剂单剂载体疫苗的精英运动员接种 COVID-19 疫苗后的免疫反应。
在接种 COVID-19 疫苗(56 剂 mRNA(BNT162b2/mRNA-1273),16 剂载体(Ad26.COV.2)疫苗)前后,从 72 名运动员的血液样本中检测免疫球蛋白 G(IgG)抗体滴度、中和活性、CD4 和 CD8 T 细胞。还记录了副作用和训练时间损失。
与一剂载体疫苗相比,两剂 mRNA 疫苗(mRNA:5702 BAU/ml;4343 BAU/ml(中位数),载体:61 BAU/ml;52 BAU/ml,p<0.01),其 IgG 抗体的中和活性(99.7%;10.6%,p<0.01)和 SARS-CoV-2 刺突特异性 CD4 T 细胞(0.13%;0.05%;p<0.01)的诱导明显更为显著。载体疫苗后 SARS-CoV-2 刺突特异性 CD8 T 细胞水平(0.15%)明显高于 mRNA 疫苗(0.02%;p<0.01)。当最初接受载体疫苗的运动员接受 mRNA 疫苗加强免疫时,IgG 抗体(至 3456 BAU/ml;p<0.01)、中和活性(至 100%;p<0.01)、CD4(至 0.13%;p<0.01)和 CD8 T 细胞(至 0.43%;p<0.01)显著增加。与两剂 mRNA 方案相比,抗体反应较低(p<0.01),中和活性(p<0.01)和 CD8 T 细胞(p<0.01)反应较高,而 CD4 T 细胞反应无显著差异(p=0.54)两种方案之间。疫苗接种方案之间的累积训练损失(3 天)无显著差异(p=0.46)。
针对 SARSCoV-2 的 mRNA 和载体疫苗似乎在运动员中诱导了不同模式的免疫反应。单次注射载体疫苗后的免疫诱导明显通过异源增强剂得到优化。疫苗反应温和且短暂。